Alpha 2.0
Login Register
» Authors » Nicholas Zdenkowski

Nicholas Zdenkowski

Explore the profile of Nicholas Zdenkowski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 436
Followers 0
Related Specialties
Oncology
General Medicine
Endocrinology
Top 10 Co-Authors
Rob Sanson-Fisher
Phyllis Butow
Charles Douglas
Alix Hall
Anne Herrmann
Frances M Boyle
Amy Waller
Hiroji Iwata
Frances Boyle
Laura Wall
Published In
Lancet Oncol
Support Care Cancer
Breast
Asia Pac J Clin Oncol
J Natl Compr Canc Netw
Affiliations
Soon will be listed here.
Recent Articles
1.
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
Zdenkowski N, Kuper-Hommel M, Niman S, Francis P, Baron-Hay S, Fox W, et al.
Lancet Oncol . 2025 Mar; 26(3):367-377. PMID: 40049198
Background: The optimal scheduling of PD-1 inhibitors with neoadjuvant chemotherapy in patients with early triple-negative breast cancer is unknown. We aimed to investigate the activity of two differing schedules of...
2.
Risk of Cancer Recurrence Exerts the Strongest Influence on Choice Between Active Surveillance and Thyroid Surgery as Initial Treatment for Low-Risk Thyroid Cancer: Results of a Discrete Choice Experiment
Hampton J, Cooper G, Wall L, Rowe C, Zdenkowski N, Fradgley E, et al.
World J Surg . 2025 Mar; PMID: 40044452
Background: Treatment options for low-risk differentiated thyroid cancer (DTC) include active surveillance (AS), hemithyroidectomy (HT), or total thyroidectomy (TT). Improved understanding of patient values and preferences is required to inform...
3.
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, et al.
Br J Clin Pharmacol . 2025 Feb; PMID: 39988750
Aim: PREDICT-5FU aimed to document 5-fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses...
4.
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review
Jiang M, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, et al.
Eur J Surg Oncol . 2024 Jul; 50(10):108554. PMID: 39059194
Accurate information about locoregional treatments in breast cancer neoadjuvant systemic therapy (NST) trials is vital to support surgical decision-making and allow meaningful interpretation of long-term oncological outcomes. This systematic review...
5.
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project
Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, et al.
BMJ Open . 2024 Apr; 14(4):e084488. PMID: 38643011
Introduction: Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to therapy is prognostic and allows locoregional and adjuvant systemic treatments to be...
6.
Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Hampton J, Alam A, Zdenkowski N, Rowe C, Fradgley E, ONeill C
Thyroid . 2024 Feb; 34(5):541-558. PMID: 38368547
Despite excellent survival rates, health-related quality of life detriments are common in differentiated thyroid cancer survivors and can be driven by fear of cancer recurrence (FCR). This review aims to...
7.
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial
Cuzick J, Chu K, Keevil B, Brentnall A, Howell A, Zdenkowski N, et al.
Lancet Oncol . 2023 Dec; 25(1):108-116. PMID: 38070530
Background: An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testosterone in postmenopausal women, but little is known about how these hormones affect response...
8.
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
Mann G, Skandarajah A, Zdenkowski N, Hughes J, Park A, Petrie D, et al.
Lancet . 2023 Dec; 403(10423):261-270. PMID: 38065194
Background: Adjuvant breast radiotherapy as a standard component of breast-conserving treatment for early cancer can overtreat many women. Breast MRI is the most sensitive modality to assess local tumour burden....
9.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol . 2023 Aug; 41(33):5118-5130. PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...
10.
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
Zhou M, Wang S, Wan N, Yuan S, Hu X, Zhou W, et al.
Ann Transl Med . 2023 Jan; 10(24):1387. PMID: 36660637
Background: Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is...